Table 1 Characteristics in the overall SpA population and in axSpA, pSpA and PsA patients
Overall SpA population N = 4185 | axSpA N = 2719 | pSpA N = 433 | PsA N = 1033 | |
|---|---|---|---|---|
Age, mean (SD) | 44.6 (13.8) | 41.98 (13.0) | 44.18 (14.4) | 51.82 (13.0) |
Sex male | 2724 (61.0%) | 1858 (68.3%) | 203 (46.9%) | 501 (48.5%) |
Disease duration (SD) | 14.50 (11.38) | 14.35 (11.09) | 10.06 (9.46) | 16.75 (12.26) |
HLAB27 positivity | 2066/3120 (66.2%) | 1709/2168 (78.8%) | 197/316 (62.3%) | 86/474 (18.1%) |
Psoriasis confirmed by a dermatologist | 1113/4464 (24.9%) | 154/2718 (5.7%) | 53/433 (12.2%) | 894/1033 (86.5%) |
Uveitis ever | 738 (16.5%) | 588 (21.6%) | 75 (17.3%) | 27 (2.6%) |
Inflammatory bowel disease (IBD) | 275 (6.15%) | 132 (4.9%) | 25 (5.7%) | 6 (0.6%) |
Peripheral joint disease ever (arthritis) | 2541 (57%) | 978 (36%) | 410 (94.7%) | 938 (90.8%) |
Dactylitis | 685 (15.3%) | 164 (6.0%) | 100 (23.1%) | 382 (36.9%) |
Fibromyalgia (rheumatologist’s opinion) | 400 (9%) | 212 (7.8%) | 48 (11.0%) | 120 (11.6%) |
Fibromyalgia (FiRST) | 775 (18.7%) | 427 (17.2%) | 69 (17.6%) | 245 (24.9%) |
BASDAI mean (SD) | 3.8 (2.4) | 3.7 (2.4) | 4 (2.4) | 4.3 (2.5) |
BASFI mean (SD) | 2.99 (2.6) | 2.97 (2.6) | 2.78 (2.6) | 3.14 (2.7) |
ASDAS-CRP mean (SD) | 2.5 (1.14) | 2.5 (1.1) | 2.6 (1.2) | 2.6 (1.1) |
NSAIDs prescribed for any indication | 3952/4185 (94.5%) | 2574/2719 (94.7%) | 423/433 (97.7%) | 955/1033 (92.4%) |
NSAIDs prescribed for enthesitis | 1228/3952 (31.1%) | 757/2574 (29.4%) | 151/423 (35.7%) | 320/955 (33.5%) |
csDMARDs prescribed for any indication | 2499/4185 (59.7%) | 1182/2719 (43.5%) | 370/433 (85.4%) | 947/1033 (91.7%) |
csDMARDs prescribed for enthesitis | 665/2499 (26.6%) | 326/1182 (27.5%) | 101/370 (27.3%) | 194/947 (20.4%) |
bDMARDs prescribed for any indication | 2177/4185 (52.1%) | 1378/2719 (50.6%) | 197/433 (45.5%) | 602/1033 (58.3%) |
bDMARDs prescribed for enthesitis | 417/2177 (19.2%) | 230/1378 (16.7%) | 56/197 (28.4%) | 131/602 (21.8%) |